HGSNAT Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population disrupting HGSNAT in A-549 lung adenocarcinoma cells. This model eliminates heparan-alpha-glucosaminide N-acetyltransferase activity, essential for lysosomal heparan sulfate degradation. The polyclonal format comprises pooled gene-edited cells, enabling studies of heterogeneous knockout effects while avoiding clonal artifact.
The A-549 host cell line, derived from a human pulmonary adenocarcinoma, is a widely used epithelial model for lung cancer biology. It exhibits adherent growth and type II alveolar characteristics, facilitating research into oncogenic signaling, drug resistance, and metabolic reprogramming. In the context of HGSNAT disruption, these cells permit investigation of how defective heparan sulfate catabolism impacts cancer cell physiology, given the roles of heparan sulfate proteoglycans in adhesion, proliferation, and metastasis.
HGSNAT catalyzes the acetylation of terminal ??-glucosaminide residues on heparan sulfate, a prerequisite for its lysosomal breakdown by downstream hydrolases SGSH, NAGLU, and IDUA, with ??-glucuronidase (GUSB) further processing the sugar chain. The enzyme interacts with lysosomal membrane proteins LAMP1 and LAMP2, and its activity is tightly coupled to lysosomal acidification and autophagic flux. Upstream, HGSNAT expression is regulated by TFEB, a master transcription factor for lysosomal biogenesis, which is under control of mTORC1 sensing of nutrient deprivation. MITF transcription factors may also modulate HGSNAT levels. Loss of HGSNAT leads to unacetylated heparan sulfate fragment accumulation, disrupting lysosomal integrity, impairing autophagy (LC3-II clearance), and altering glycosaminoglycan metabolism.
In A-549 adenocarcinoma cells, HGSNAT knockout creates a unique model that bridges lysosomal storage pathology and cancer glycobiology. The ensuing heparan sulfate accumulation mirrors the biochemical defect of mucopolysaccharidosis type IIIC (Sanfilippo syndrome C), yet within a malignant epithelial background, it enables exploration of how lysosomal dysfunction influences tumor cell proliferation, stress responses, and sensitivity to autophagy-modulating agents. This system may uncover vulnerabilities specific to cancer cells with impaired glycosaminoglycan catabolism.
Researchers can employ these polyclonal knockout cells for quantitative heparan sulfate profiling by LC-MS/MS, glycosaminoglycan quantification, and Western blotting to confirm HGSNAT ablation. Lysosomal pathology is assessed via immunofluorescence for LAMP1/LAMP2, lysosomal pH measurements, and transmission electron microscopy to detect storage vacuoles. Autophagic flux studies (LC3-II turnover ?? lysosomal inhibitors) and analyses of TFEB/mTORC1 signaling provide functional readouts. This product supports research into lysosomal storage disorders, autophagy-lysosome pathway, and cancer glycobiology. For technical inquiries, please contact Ascent Research.
